NA
RIGL icon

NewEdge Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

NewEdge Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$1.29K – 3623
2023
Q2 		$1.29K Hold
100
– – ﹤0.01% 3202
2023
Q1 		$1.32K Hold
100
– – ﹤0.01% 3115
2022
Q4 		$2 Buy
+100
New +$917 ﹤0.01% 3956

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NewEdge Advisors's RIGL Position: Q3 2023 in Review

NewEdge Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 100 shares — an estimated $1.29K sold.

NewEdge Advisors first reported a position in RIGL in Q4 2022 and held it in 3 quarters. The position peaked at $1.32K in Q1 2023. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

  • NewEdge Advisors reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • NewEdge Advisors sold 100 Rigel Pharmaceuticals shares in Q3 2023, an estimated $1.29K.
  • NewEdge Advisors first reported a position in Rigel Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • NewEdge Advisors's Rigel Pharmaceuticals position peaked at $1.32K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.